Investment portfolio.
We provide smart capital for Belgian innovation and driving socio-economic growth.
Our role is to create
sustainable long-term value.
all our investments are driven by our values.
NEUVASQ BIOTECHNOLOGIES
Détention du capital11.36 %
Company that manufactures pharmaceutical products for acute neurological disorders.
NEWTON BIOCAPITAL I
Détention du capital17.67 %
The fund was created in April 2017 as a private Pricaf [investment vehicle for private equity investments] and targets companies active in the treatment of chronic diseases such as inflammatory, neurodegenerative, cardiovascular disease and cancer. The fund is geared to Belgian companies as well as European "early stage" companies such as university spin-offs.
NEWTON BIOCAPITAL II
Détention du capital19 %
The fund was created in April 2017 in the form of a private Pricaf and targets companies active in the treatment of chronic diseases such as inflammatory, neurodegenerative, cardiovascular and cancer. The fund is aimed at Belgian companies as well as European "early stage" companies such as university spin-offs.
NORMANDY HADRONTHERAPY/NHA (IBA)
Détention du capital9.77 %
The technological solution proposed by Normandy Hadrontherapy aims to make hadrontherapy (proton therapy and carbon beam treatment) more accessible to clinical treatment centres. The technological solution proposed by NHa aims to replace the synchrotron with an isochronous cyclotron, which is a more compact piece of equipment, significantly less expensive and easier to operate and maintain than the synchrotons currently in use.
NUCLEIS
Détention du capital17.20 %
Nucleis specialises in the production in a GMP environment of radiopharmaceutical medicines for human use (including nuclear and non-nuclear medical imaging). It is the result of a spin-off process of the Cyclotron Research Centre of the University of Liege.
NXTPORT
Détention du capital24.57 %
NxtPort manages a data platform used to collect, group and then centralise data of the different links in the logistical supply chain related to activities in the Port of Antwerp. The platform is designed to improve the sharing of data, thus enhancing the transparency and efficiency of this process.
OMXE INVEST
Détention du capital12.95 %
Company that manages public APCO under Belgian or foreign law.
OMXE PARTNER
Détention du capital0.00 %
Company that provides holiday booking services.
ONCO DNA
Détention du capital17.81 %
The company is active in the genetic and protein characterisation of tissue samples sent for analysis by oncologists. It was incorporated in December 2012 and benefits from strong cooperation with the Institute of Genetic Pathology -- a cooperation that has avoided the need for heavy investment in medical analysis.
OPEN SKY TECHNOLOGIES FUND BELGIUM POOL
Détention du capital0.00 %
Company that focuses on seed capital investments.
PDC LINE PHARMA
Détention du capital21.46 %
This company is a spin-off of the French national blood service <em>l'Etablissement français du sang</em> (EFS). It is active in immuno-oncology, i.e. the production of therapeutic vaccines against cancer. PDC Line Pharma has two products: one in the field of melanomas and one in the field of lungs.
Fors Capital Partners
Détention du capital14.72 %
An international investment fund, created in collaboration with the Brazilian development bank BNDES. The fund is active in the sectors of energy efficiency and the treatment and management of wastewater and solid waste, and focusses on innovative and sustainable technologies in Brazil.
PHARMAFLUIDICS
Détention du capital16.22 %
This is a spin-off from the Free University of Brussels and is developing a new generation of separation columns for screening molecules in fluids with a complex chemical composition. By commercialising its spearhead technology, the μPAC microchip, PharmaPhluidics wants to make a breakthrough in the world of complex separations and analyses of biological samples such as biopsies.
PROFINPAR FUND
Détention du capital13.28 %
Profinpar Fund is a fund of businesses pursuing a partner relationship with family-owned SMEs and their shareholders. What makes Profinpar special is that it links an offer of venture capital to the know-how of its numerous investors. Profinpar Fund wants to act as an active partner and growth catalyst by supporting the transfer or the optimisation of companies.
QBIC FEEDER FUND
Détention du capital18.37 %
Qbic is an inter-university (UGent, UAntwerpen and VUBrussel) investment fund focusing on the transformation of technological breakthroughs into sustainable business